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Airway smooth muscle (ASM) plays a key role in bronchomotor tone, as well as in structural
remodeling of the bronchial wall. Therefore, ASM contraction and proliferation significantly
participate in the development and progression of asthma.Many contractile agonists also behave
as mitogenic stimuli, thus contributing to frame a hyperresponsive and hyperplastic ASM pheno-
type. In this review, the molecular mechanisms and signaling pathways involved in excitatione
contraction coupling and ASM cell growth will be outlined. Indeed, the recent advances in
understanding the basic aspects of ASM biology are disclosing important cellular targets,
currently explored for the implementation of new, more effective anti-asthma therapies.
ª 2008 Published by Elsevier Ltd.Introduction
Once believed to be just a contractile tissue, airway smooth
muscle (ASM) is instead characterized, in addition to
contraction, by many other biological and functional
properties including regulation of bronchomotor tone,348 6412311; fax: þ39 06
t.it (M. Cazzola).
8 Published by Elsevier Ltd.perpetuation and amplification of airway inflammation, as
well as active participation in bronchial remodeling.1
Therefore, ASM plays a central role in almost all the patho-
physiologic and clinical aspects of asthma such as reversible
airway obstruction, bronchial hyperresponsiveness (BHR) to
direct and indirect contractile stimuli, chronic inflamma-
tion and airway structural changes. In this regard, during
the last few years significant advances have been made in
elucidating the molecular events underlying ASM functions
related to calcium responses, synthetic phenotype and hy-
perplastic behaviour. Of course, a better knowledge of
1174 G. Pelaia et al.these phenomena may enable to improve our understand-
ing of asthma and to develop new therapeutic strategies
directly targeted to ASM. Within such a context, the aim
of the present review is to briefly outline the basic mecha-
nisms responsible for excitationecontraction coupling and
ASM cell proliferation, with a particular focus on the
relevance of these subjects to asthma.
Excitationecontraction coupling
ASM contraction plays an important physiologic role in that
contributes to match ventilation with perfusion, confers
mechanical stability to noncartilaginous airways and
prevents toxic inhaled agents from reaching the alveolar
air spaces. However, the exaggerated ASM contractile
response characterizing BHR, a constant feature of asthma,
is the main pathophysiologic factor involved in the de-
velopment of reversible airway obstruction. BHR consists of
a reduced threshold to a wide range of contractile stimuli
acting either directly on ASM by activating specific cell
membrane receptors, or indirectly through neural pathways
and/or the release of bronchoconstrictive mediators from
both inflammatory and structural cells.2 Table 1 provides
a list of the most important contractile agonists relevant
to asthma (Fig. 1).
Similar to all contractile phenomena, ASM contraction
also depends on calcium ions (Ca2þ). Nevertheless, ASM ex-
hibits peculiar features that clearly differentiate it from
skeletal and cardiac muscles, as well as from vascular
smooth muscles. In such tissues, excitationecontraction
coupling largely results from membrane depolarization
leading to Ca2þ influx via voltage-dependent Ca2þ channels.
In fact, Ca2þ channel blockers are very useful in modulating
cardiac activity and treating hypertension. By contrast,
these drugs exert only negligible effects on experimentally
induced bronchoconstriction.3,4 The modest contribution
provided by extracellular Ca2þ sources to excitatione
contraction coupling in ASM, may be at least in part
explained by the electrical properties of ASM cells. Their
membrane potential spontaneously oscillates thus giving
rise to the so-called slow waves, whose amplitude and
frequency are approximately 8e12 mV and 20e50 even-
ts min1, respectively.5,6 This myogenic activity is likelyTable 1 Main bronchoconstrictive mediators involved in
asthma
Agonist Receptor
Acetylcholine M3 muscarinic
Neurokinins NK1/NK2
Cysteinyl leukotrienes (LTC4/D4/E4) CysLT1R
Prostaglandin F2a FP
Prostaglandin D2 DP2
Thromboxanes TP
Histamine H1
Endothelin-1 ETA/ETB
Bradykinin BK1
Adenosine A1
Serotonin 5-HT2a/5-HT2c
Thrombin PAR1/2/3due to a constitutive production of arachidonic acid metab-
olites in ASM.7 However, slow waves usually cannot be con-
verted into action potentials because of a strong outward
rectification that counteracts any tendency to ASM depolar-
ization. Such rectifying currents are mediated by the open-
ing of large conductance Ca2þ-activated and, especially,
delayed-rectifier Kþ channels, responsible for repolarizing
or hyperpolarizing ion fluxes which confer a remarkable
electrical stability to ASM.8 Therefore, generation of spiking
action potentials and the consequent activation of voltage-
dependent Ca2þ channels can occur in ASM only under the
experimental blockade of Kþ rectifying efflux, operated by
depolarizing agents such as tetraethylammonium (TEA).
This implies that calcium ions required for ASM contraction
mostly come from intracellular stores.
Dynamics of Ca2D responses
Studies performed with Ca2þ-sensitive fluorescent dyes
have demonstrated that contractile agonists elicit in ASM,
with regard to intracellular Ca2þ, a biphasic response.9
Initially, cytosolic free Ca2þ concentration increases from
baseline levels, ranging from 100 to 200 nM, up to 800e
1000 nM. This sharp and rapid rise, responsible for tension
development, is then followed by a sustained plateau char-
acterized by Ca2þ levels slightly above the resting values,
which is associated with tension maintenance. Moreover,
contractile agents such as acetylcholine (ACh) induce
regenerative and propagating Ca2þ oscillations,10 whose
functional role has not yet been fully understood. The ini-
tial Ca2þ spike is due to a release of Ca2þ from intracellular
stores, especially the sarcoplasmic reticulum (SR), induced
by inositol 1,4,5-trisphosphate (IP3).
11 The latter originates
from stimulation of contractile agonist receptors coupled
to a Gq-type of G protein, responsible for activation of
the b1 isoform of phospholipase C (PLC-b1), which in turn
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2)
thus producing the two second messengers IP3 and 1,2-
diacylglycerol (DAG).12 IP3 diffuses through the cytosol
and binds to its specific receptor (IP3R) located on the SR,
thereby mobilizing the IP3-sensitive pool of intracellularly
stored Ca2þ, whereas DAG activates protein kinase C
(PKC), which affects the sensitivity of the contractile appa-
ratus to Ca2þ. Indeed, IP3R is an agonist-operated Ca
2þ
channel, characterized by a homotetrameric structure con-
sisting of four subunits, each having a molecular weight of
about 260 kDa.13 The fast and transient elevation of cyto-
solic Ca2þ concentration, induced by IP3, is responsible
for the sequential occupancy of the four Ca2þ binding
sites of calmodulin (CaM). The Ca2þeCaM complex in turn
opens and activates the enzymatic domain of myosin light
chain kinase (MLCK), which phosphorylates a specific ami-
no acid residue (serine 19) of the regulatory, 20 kDa light
chain (MLC20) subunit of myosin. MLCK is overexpressed
in ASM cells of asthmatic patients.14 When MLCK is phos-
phorylated by 30e50 cyclic adenosine monophosphate
(cAMP)-dependent protein kinase A (PKA), for example as
a consequence of b-adrenoceptor stimulation, its affinity
for Ca2þeCaM decreases, thus resulting in reduced MLCK
activity and ASM contraction. MLC20 phosphorylation is in-
deed essential to trigger cross-bridge cycling, i.e. the move-
ment of myosin heads along actin filaments. The contractile
Figure 1 Signal transduction pathways involved in ASM contraction. Interaction of contractile agonists with their G protein-cou-
pled receptors (GPCR) leads to activation of phospholipase C-b (PLCb), which hydrolyzes phosphatidylinositol 4,5-bisphosphate
(PIP2), thus producing the two second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to its recep-
tor (IP3R) on the sarcoplasmic reticulum (SR), thereby releasing Ca
2þ that activates Ca2þ-calmodulin-dependent myosin light chain
kinase (MLCK). MLCK phosphorylates myosin light chain (MLC), leading to ASM contraction, which is terminated by MLC phosphatase
(MLCP). In addition to IP3, Ca
2þ release from SR is also stimulated by agonist-induced activation of CD38, producing cyclic ADP-
ribose (cADPR) that presumptively (broken arrow with question mark) interacts with ryanodine receptors (RyR). Furthermore,
Ca2þ can flow across plasma membrane through channels including store-operated Ca2þ channels (SOCC), receptor-operated
Ca2þ channels (ROCC) and voltage-operated Ca2þ channels (VOCC). VOCC activation is, however, usually prevented by outward
ion currents mainly due to opening of delayed-rectifier Kþ channels (K-DR). ASM contractile responses also depend on mechanisms
of Ca2þ sensitization, mediated by MLCP inhibition induced by DAG/PKC/CPI-17 and Rho/Rho kinase (ROK) pathways; RhoA is
activated by guanine nucleotide exchange factors (GEFs).
ASM contraction and proliferation 1175model of ASM is thereby consistent with a sliding-
filament mechanism in which actomyosin cross-bridges,
powered by ATP hydrolysis catalyzed by myosin ATPase,
are responsible for tension development.15 As a result of
a homeostatic process, the increase in cytosolic free Ca2þ
levels is then rapidly and almost completely reverted by a re-
uptake into the SR mainly mediated by the sarcoplasmic/
endoplasmic reticulum calcium ATPase (SERCA), that
whereby refills the previously depleted intracellular Ca2þstores; the latter are also repleted by transmembrane
influxes of extracellular Ca2þ through voltage-activated
Ca2þ channels, store-operated Ca2þ channels, and voltage-
independent, non selective cation channels such as transient
receptor potential channels.4,7,16 On the other hand, SERCA
is one of the cellular targets of b-adrenergic agonists, which
relax ASM also by promoting Ca2þ re-sequestration into in-
tracellular stores.17 Moreover, b-sympathomimetics inter-
fere with intracellular Ca2þ mobilization also by reducing
1176 G. Pelaia et al.IP3-induced Ca
2þ release via cAMP/PKA-mediated phosphor-
ylation-dependent inhibition of IP3R.
18 Asthmatic subjects
aremuchmore dependent than normal individuals on endog-
enous modulation of bronchomotor tone exerted by cate-
cholamines, as shown by the negative consequences of
b-adrenergic blockade on both ASM contraction and BHR to
methacholine.19,20
Hence, with regard to ASM contraction elicited by ACh
and many other excitatory agents, IP3 is crucial for initia-
tion of intracellular Ca2þ oscillations. In particular, an
important role in Ca2þ oscillations may be played by a peri-
odical Ca2þ release through activated IP3R, triggered by
cyclical Ca2þ fluctuations within SR lumen.21 Once initiated
in ASM cells, however, these oscillations are not abolished
by heparin, an IP3R antagonist.
22 Also in vivo, inhaled
heparin is able to attenuate, but not to completely sup-
press, bronchoconstriction induced in asthmatic patients
by methacholine and other contractile stimuli.23,24 ACh-
induced intracellular Ca2þ oscillations can be inhibited by
antagonists of the ryanodine receptor (RyR), such as ryano-
dine and ruthenium red.25,26 These observations imply that
Ca2þ release through RyR channels cooperates with IP3-
mediated Ca2þmobilization to integrate the Ca2þ responses
of ASM triggered by contractile agonists. In particular, the
involvement of RyR channels, which are embedded in the
SR membrane, is essential for propagation of intracellular
Ca2þ oscillations in ASM cells. RyR is activated by the nucle-
otide metabolite cyclic ADP-ribose (cADPR) synthesized
by CD38, a transmembrane glycoprotein which converts
b-NAD (nicotinamide adenine dinucleotide) to cADPR.22
However, the mechanism whereby stimulation of G pro-
tein-coupled receptors by contractile agonists leads to
CD38 activation and cADPR production has not yet been elu-
cidated. Moreover, it is not clear how extracellularly gener-
ated cADPR reaches its site of action, located on Ca2þ
intracellular stores; the involvement of a specific carrier
that shuttles cADPR across the plasma membrane, can
thus be reasonably hypothesized.
cADPR contributes to Ca2þ release from SR via several
different mechanisms. It could perhaps interact directly
with RyR channels, but current evidence suggests that
cADPR acts mainly indirectly, by binding to some accessory
proteins.22 In this regard, the 12.6-kDa tacrolimus (FK506)-
binding protein (FKBP12.6) plays a very important role, in
that it maintains RyR in an inactive state 27; the interaction
of cADPR with FKBP12.6 causes its dissociation from RyR,
and the latter becomes thereby activated. Another indirect
Ca2þ releasing process implies that cADPR can stimulate
CaM, which in turn activates RyR either directly or indi-
rectly, via RyR phosphorylation catalyzed by CaM-kinase
II.28 CaM-mediated mechanisms may explain the relevant
contribution given by cADPR to the so-called phenomenon
of Ca2þ-induced Ca2þ release,29 which is very effective in
propagating intracellular Ca2þ oscillations throughout the
cytosol of ASM cells. cADPR-dependent mobilization of
intracellular Ca2þ is not affected by heparin, thus ruling
out any involvement of cADPR in IP3R activation.
In light of all such considerations, it can be argued that IP3
andcADPRactasCa2þ-mobilizing secondmessengersforamul-
titudeofcontractileagonists,bothbeing responsible inASMfor
a synergistic coordination and integration of the intracellular
Ca2þ responses underlying excitationecontraction coupling.Effects of proinflammatory cytokines
on generation of Ca2D-mobilizing
second messengers
Inflammatory cytokines can further enhance agonist-
induced contractility, primarily by increasing the magni-
tude of Ca2þ responses mediated by intracellular second
messengers. It is now clear that these mechanisms signifi-
cantly contribute to the molecular pathogenesis of BHR.30
In particular, it has been shown that tumour necrosis
factor-a (TNF-a) and interleukin-1b (IL-1b) are able to
augment Ca2þ responses induced by carbachol, bradykinin
and thrombin.31 Moreover, Ca2þ responses to contractile
agonists may also be increased by interleukin-13 (IL-13),32
a T helper 2 (Th2)-derived cytokine that plays a key role
in the development of allergic asthma. These cytokines
exert such effects at least in part by inducing, in ASM cells,
the expression of CD38 and the related production of
cADPR.16 In addition to cholinergic agents, also endothelin
(ET) and bradykinin utilize the CD38/cADPR/Ca2þ signaling
pathway,31,33 which is hyperactivated in asthma as a result
of the exposure of ASM cells to high levels of proinflamma-
tory cytokines. The latter could also indirectly stimulate IP3
generation through an up-regulation of the various compo-
nents of the signaling machinery, such as Gq proteins and
Gq-coupled receptors linked to phosphoinositide metabo-
lism. For instance, IL-13 stimulates the expression of the
CysLT1 receptor of leukotrienes,34 thus possibly enhancing
airway responsiveness to these mediators. Furthermore,
in ASM cell cultures IL-1b is able to increase the density
of B2 bradykinin receptors, as well as bradykinin-induced
phosphoinositide turnover.35 TNF-a stimulates ASM expres-
sion of PLC-activating Gq proteins, thereby promoting IP3
production.36 On the other hand, proasthmatic cytokines
can also exert an indirect, negative interference on b-
agonist functions, including b-adrenoceptor-mediated inhi-
bition of PIP2 hydrolysis and IP3 synthesis. For example,
IL-13 desensitizes ASM b2-adrenergic receptors,
37 thus
impairing the relevant role of b2-sympathomimetics in mod-
ulation of intracellular Ca2þ fluxes.
Therefore, an inflammatory microenvironment like that
characterizing asthmatic airways is likely to favour, via
several different mechanisms involved in Ca2þ mobiliza-
tion, the acquisition of a hypercontractile phenotype.
Mechanisms of Ca2D sensitization
Upon ASM exposure to contractile agonists, the initial,
transient peak in intracellular Ca2þ concentration is then
rapidly followed by a decline to a steady-state pattern,
characterized by a prolonged, but slight increase of cyto-
solic free Ca2þ above resting levels. Differently from the
first phase of Ca2þ response, mostly due to Ca2þ release
from SR, the steady-state plateau also depends on Ca2þ
influx from the extracellular space.38 In the absence of
extracellular Ca2þ, in fact, intracellular Ca2þ oscillations
can start, but cannot be maintained. Both Ca2þ re-uptake
into the SR and Ca2þ influx from the extracellular environ-
ment, therefore, contribute to replete Ca2þ stores and to
maintain intracellular Ca2þ oscillations. Anyway, similarly
to other smooth muscles, contraction of ASM persists during
ASM contraction and proliferation 1177the steady-state phase of Ca2þ responses elicited by excit-
atory agents. This functional behaviour implies an
enhanced sensitivity to Ca2þ of the contractile apparatus 15
that enables ASM to remain contracted even when intra-
cellular Ca2þ levels are only slightly increased above base-
line concentrations. It is currently thought that the main
signaling mechanisms responsible for Ca2þ sensitization
include the RhoA/Rho kinase pathway and the PKC/CPI-17
effector system.39
In addition to inducing the biosynthesis of IP3 and cADPR,
stimulation of Gq protein-coupled receptors by contractile
agonists also leads, via not yet known molecular events, to
activation of RhoA.40 The latter is a small monomeric G
protein which, under resting conditions, is associated with
the guanine nucleotide GDP and complexed into the cytosol
with the GDP dissociation inhibitor (GDI). Interaction
between contractile agonists and their Gq-coupled
receptors activates the so-called guanine nucleotide
exchange factors (GEFs), which promote the substitution
of GDP with GTP on RhoA.41 Consequently, RhoA dissociates
from GDI, and the RhoAeGTP complex can thus reach the
inner side of plasma membrane, where it interacts with
Rho kinase (ROK). This activation process is terminated
by Rho GTPase activating proteins (RhoGAPs) that hydro-
lyze Rho-bound GTP to GDP, thereby enabling RhoAeGDP
to reassociate with GDI and to be again located inside the
cytosol. Binding of Rho-GTP to ROK produces a conforma-
tional change in the kinase domain, causing an activating
autophosphorylation.39 ROK sensitizes the contractile appa-
ratus to Ca2þ through phosphorylation of the myosin bind-
ing subunit of MLC20 phosphatase (MLCP) that results in
inhibition of its enzymatic activity.42 As a consequence,
MLC20 cannot be dephosphorylated thus remaining in its
phosphorylated form, responsible for smooth muscle con-
traction. It is thus conceivable that RhoA/ROK-mediated
Ca2þ sensitization plays a key role in the molecular patho-
genesis of BHR. In fact, RhoA expression is enhanced in ASM
of antigen-sensitized, hyperresponsive mice.43 RhoA pro-
tein levels are also increased in case of TNF-a-mediated po-
tentiation of ACh-induced rat ASM contraction.44 Moreover,
contractile agonists such as ACh and ET are able to promote
Rho translocation from cytosol to plasma membrane in rat
ASM cells.45,46 Therefore, the RhoA/ROK signaling pathway
can be considered as a suitable target for the development
of new anti-asthma treatments, focused on modulation
of BHR.
MLCP activity can also be modulated by the 17-kDa
peptide CPI (C kinase-potentiated phosphatase inhibitor)-
17 that upon PKC-dependent phosphorylation becomes a
potent MLCP inhibitor.47 Activation of the PKC/CPI-17 sig-
naling route, induced by the second messenger DAG derived
from phosphoinositide turnover, thereby represents another
key mechanism involved in Ca2þ sensitization triggered by
contractile agonists interacting with their Gq-coupled
receptors expressed by ASM cells. For instance, CPI-17
expression and ACh-induced CPI-17 phosphorylation are sig-
nificantly increased in ASM of hyperresponsive rats.48 Phos-
phorylation of rat ASM CPI-17 can also be markedly
enhanced by other contractile agonists such as ET-1.49 On
the other hand, it has been suggested that PKC activation,
and of course the subsequent CPI-17 stimulation, can be
blocked by 8-bromo-cAMP in rabbit tracheal smooth musclecontracted by carbachol, as well as in human bronchial
smooth muscle exposed to leukotriene D4 (LTD4).
50 These
observations imply that Ca2þ desensitization of the contrac-
tile apparatus, mediated by the cAMP/PKA pathway, may
significantly contribute to the relaxing effects exerted on
ASM by cAMP-elevating agents such as b-adrenergic agonists
and phosphodiesterase (PDE) inhibitors.Airway smooth muscle cell proliferation
In addition to chronic inflammation, reversible airflow
limitation and BHR, another typical feature of asthma is
airway remodeling that consists of structural changes
spanning throughout the bronchial wall. In this regard it
has been suggested that the natural, gradual disease
progression can be at least in part explained by the
development of airway remodeling.51 Inflammation and re-
modeling are indeed the main characterizing elements of
the asthmatic phenotype. However, although these two as-
pects are closely correlated and affect each other by recip-
rocal, positive feedbacks, structural modifications may
occur independently of inflammation and often precede
the onset of asthma symptoms.52 Hallmarks of airway re-
modeling in asthma include epithelial shedding and goblet
cell hyperplasia, subepithelial fibrosis with abnormal depo-
sition of extracellular matrix, enhanced thickness of
smooth muscle layer, and angiogenesis of bronchial vascu-
lature.53 Tissue remodeling could provide some potential
benefits in asthma,52 in that an increased stiffness might
enable the airways to resist dynamic compression; further-
more, deposition of collagen fibres around ASM could
produce a mechanical impedance to contraction. Neverthe-
less, these theoretical advantages are largely overwhelmed
by the negative effects of airway remodeling, which results
in narrowing of the bronchial lumen, fixed airflow obstruc-
tion with impaired response to bronchodilators, and pro-
gressive loss of lung function.52 In particular, ASM bundle
thickening, responsible for the reduced airway caliber and
possibly associated with an exaggerated contractility, may
represent a relevant contributing factor to BHR.54 The in-
creased mass of ASM layer is indeed correlated with airway
responsiveness to methacholine and asthma severity.55,56
On the other hand, hypertermic treatment of airways
with radiofrequency waves (bronchial thermoplasty),
performed through bronchoscopy and aimed to decrease
ASM bulk, is able to improve BHR in patients with mild to
moderate persistent asthma for at least 2 years after ther-
moplasty.57 Within such a context, a crucial pathophysio-
logic role is thus played by the biological mechanisms
leading to the oversized ASM mass, due in part to hypertro-
phy, but especially to hyperplasia (Fig. 2).
An increased proliferation of ASM cells has been shown in
both asthmatic patients and animal models of allergic airway
inflammation.58,59 ASM mitogens include growth factors, con-
tractile agonists, and perhaps proinflammatory cytokines.
Among the first ones, a relevant proliferative action is exerted
by epidermal growth factor (EGF), insulin-like growth factors
(IGFs), platelet-derived growth factor (PDGF), and fibroblast
growth factor (FGF)-2. Interestingly, some of the agents that
induce ASM contraction, such as histamine, ET-1, substance
P, serotonin, a-thrombin, thromboxane A2 and LTD4, are also
Figure 2 Signal transduction pathways involved in ASM proliferation. ASM proliferation is induced by mitogens acting mainly via
tyrosine kinase receptors (TKR) and G protein-coupled receptors (GPCR). Stimulation of these receptors leads to activation of
p21ras proteins, which interact with downstream pathways including extracellular signal-regulated kinase (ERK) cascades and
phosphoinositide 3-kinase (PI3K). ERK and PI3K-dependent signaling molecules (PDK1, PKB/Akt, p70S6K, Rac1, etc.) cooperate in
the activation of transcription factors (SP1, CREB, NF-kB) required for cyclin D1 gene expression and cell growth.
1178 G. Pelaia et al.able to behave as mitogenic stimuli. Furthermore, in ASM
derived from asthmatic patients, when compared to normal
subjects, low levels have been found of the bronchodilating
prostaglandin E2 (PGE2),
60 which is also an inhibitor of ASM
cell growth.61 More controversial is the potential proliferative
role of inflammatory cytokines like IL-1b, IL-6, and TNF-a,
whosemitogenic action has been shown in ASM of some animal
species.1 Moreover, IL-13 is able in vitro to potentiate the
proliferative effects induced by LTD4 on human ASM.
34
The transduction pathways that originate from plasma
membrane and through the cytoplasm reach the nucleus,
activated by the interactions of several different mitogens
with their respective ASM surface receptors, converge on
a relatively limited number of intracellular signaling
modules, mainly including mitogen-activated protein
kinases (MAPK) and phosphoinositide 3-kinase (PI3K).62 In
particular, growth factors bind to receptors with intrinsic
tyrosine kinase activity, whereas contractile agonists stim-
ulate G protein-coupled receptors. Downstream from
receptor activation, the molecular events triggered by
both growth factors and contractile agonists lead to activa-
tion of the 21-kDa small GTPase, p21ras protein.63
Activated p21ras binds PI3K and the 74-kDa cytoplasmic,
serineethreonine kinase Raf-1.59 The latter is responsible
for activation of MAPK cascades via phosphorylation ofMEK1 (MAPK/ERK kinase 1), which in turn phosphorylates
and activates extracellular signal-regulated kinases (ERK)
1 and 2. Activated ERK1/2 is able to induce cyclin D1
expression in airway myocytes,64 thus promoting a progres-
sion of the cell cycle from G1 to S phase and ASM prolifer-
ation. In fact, activation of the nuclear complexes
constituted by cyclins and cyclin-dependent kinases (cdk)
is required for hyperphosphorylation of the retinoblastoma
restriction protein (Rb), resulting in its reduced affinity for
the elongation factor E2F 59; dissociation from Rb activates
E2F, which is responsible for stimulation of DNA polymerase
and transcriptional induction of specific S phase-dependent
genes. In human ASM, a prolonged ERK activation is indeed
correlated with DNA synthesis and cell proliferation, which
can be markedly attenuated by the MEK1 inhibitors
PD98059 and U0126, respectively.65,66 Furthermore, ASM
mitogenesis is significantly inhibited by antisense oligo-
deoxynucleotides targeted to ERK1/2 mRNAs.67 In addition
to ERK, also other members of the MAPK superfamily such
as p38 and c-Jun N-terminal kinase (JNK) may be involved
in induction of ASM growth. In human cultured ASM
myocytes, Rb phosphorylation, DNA synthesis, and cell
proliferation induced by basic FGF are mediated by p38
MAPK activation, thus suggesting that the antimitogenic ef-
fects of the p38 inhibitor SB203580 are due to an arrest of
ASM contraction and proliferation 1179cell cycle at late G1 phase.68 In ASM of sensitized mice, p38
MAPK plays indeed a key role in mediating the proliferative
response elicited by allergen challenge.69 Moreover, JNK
has also been shown to induce ASM mitogenesis in
allergen-sensitized rats and mice 70,71; therefore, in asthma
this MAPK pathway could synergize with ERK and p38 in
promoting the acquisition of a hyperplastic ASM phenotype.
Together with MAPK, PI3K is the other main signaling
pathway activated by mitogenic stimuli in ASM. Upon
p21ras-dependent activation, PI3K phosphorylates
phosphatidylinositol membrane lipids at the D-3 position
of the inositol ring, thus producing the second messenger
phosphatidylinositol-3,4,5-trisphosphate (PIP3).
72 PIP3
binds and recruits to the plasma membrane a group of
signaling molecules such as serineethreonine kinases
(Akt/PKB, PDK1) and exchange factors for GTP binding
proteins (Grp1, Rac), which act as important regulators of
cell cycle and cell survival/proliferation. In particular,
protein kinase B (PKB) phosphorylates Bad thus inhibiting
its proapoptotic functions, and also represses transcription
of the cdk inhibitor p27kip1, thereby allowing cell cycle
transition.73 A relevant downstream target of phosphoinosi-
tide-dependent kinase 1 (PDK1) is the 70 kDa ribosomal S6
kinase (p70S6K), whose rapamycin-mediated inhibition
leads to a reduction in cyclin D1 mRNA and protein levels,74
as well as to a marked attenuation of growth factor-
induced DNA synthesis in both bovine and human ASM.75,76
Furthermore, the PIP3-regulated Rac1 factor is also
required for cyclin D1 expression in bovine tracheal myo-
cytes.77 Therefore, the PI3K effector system plays a crucial
role in inducing ASM mitogenesis, as it has been shown with
regard to the proliferative actions of PDGF and thrombin.78
However, maximal proliferation of ASM is probably depen-
dent on parallel activation of both PI3K and MAPK
pathways.59
ASM growth is not only stimulated by mitogenic mecha-
nisms, but also finely modulated by antiproliferative signals,
among which a relevant function is exerted by the tran-
scription factor CCAAT/enhancer binding protein-a (C/
EBPa). C/EBPa controls the rate of ASM proliferation by
inducing the synthesis of the cell cycle inhibitor p21waf1/cip1.
In this regard, it has been reported that the simultaneous
addition to ASM cell growth medium of a glucocorticoid
(budesonide) and a b2-agonist (formoterol) results in a syner-
gistic activation of the p21waf1/cip1 gene promoter, paral-
leled by a marked antiproliferative effect.79 However, the
antimitogenic action of glucocorticoids has not been con-
firmed in primary cultures of bronchial smooth muscle cells
obtained from asthmatic patients, which do not express C/
EBPa.80 Therefore, it can be argued that a deficit of C/EBPa
in ASM of subjects with asthma favours the acquisition of
a hyperplastic phenotype and impairs the potential antipro-
liferative effect of glucocorticoids.81 This latter action can
indeed be restored by experimentally introducing, through
an expression vector, the C/EBPa protein inside asthmatic
ASM cells.80
Conclusions
Current evidence clearly indicates that ASM plays a key
role in the pathogenesis of asthma. In particular, both
contractile and proliferative responses significantlycontribute, together with the synthetic properties of ASM
cells, to the pathophysiological changes underlying BHR and
airway remodeling. Therefore, elucidation of the complex
signaling pathways involved in excitationecontraction cou-
pling and cell growth is essential to understand how ASM is
actively implicated in shaping the biological asthmatic
microenvironment. Within such a context, the recent in-
sights into the molecular mechanisms responsible for ASM
contraction and proliferation may unveil new potential
targets (e.g. cADPR, ROK, MAPK, PI3K, C/EBPa) for the
development of future, more effective bronchodilating,
anti-hyperresponsive and anti-remodeling therapeutic
strategies, eventually capable of affecting the natural
history of asthma.Conflict of interest statement
None of the authors have a financial relationship with
a commercial entity that has an interest in the subject of
this manuscript.
References
1. Lazaar AL, Panettieri RA. Airway smooth muscle as a regulator
of immune responses and bronchomotor tone. Clin Chest Med
2006;27:53e69.
2. Marsico SA, Pelaia G. Airways smooth muscle response to
biological stimuli. Monaldi Arch Chest Dis 1998;53:97e9.
3. Marsico SA, Pelaia G, Grembiale RD, Pugliese C, Cellamare P.
Calcium ions and airway smooth muscle contraction. In:
Olivieri D, Bianco S, editors. Airway obstruction and inflamma-
tion. Progress in respiration research, vol. 24. Basel: Karger;
1990. p. 26e34.
4. Sanderson MJ, Delmotte P, Bai Y, Perez-Zogbhi JF. Regulation
of airway smooth muscle cell contractility by Ca2þ signaling
and sensitivity. Proc Am Thorac Soc 2008;5:23e31.
5. Tomita T. Electrical properties of airway smooth muscle. In:
Coburn RF, editor. Airway smooth muscle in health and
disease. New York: Plenum Press; 1989. p. 151e67.
6. Thirstrup S. Control of airway smooth muscle tone. I e electro-
physiology and contractile mediators. Respir Med 2000;94:
328e36.
7. Hirota S, Helli P, Janssen LJ. Ionic mechanisms and Ca2þ han-
dling in airway smooth muscle. Eur Respir J 2007;30:114e33.
8. Pelaia G, Gallelli L, Vatrella A, Grembiale RD, Maselli R, De
Sarro GB, et al. Potential role of potassium channel openers
in the treatment of asthma and chronic obstructive pulmonary
disease. Life Sci 2002;70:977e90.
9. Murray RK, Kotlikoff MI. Receptor-activated calcium influx in
human airway smoothmuscle cells. J Physiol 1991;435:123e44.
10. Nuttle LC, Farley JM. Frequency modulation of acetylcholine-
induced oscillations in Ca2þ and Ca2þ-activated Cl current
by cAMP in tracheal smooth muscle. J Pharmacol Exp Ther
1996;277:753e60.
11. Berridge MJ. Inositol trisphosphate and calcium signaling.
Nature 1993;361:315e25.
12. Hall IP. Second messengers, ion channels and pharmacology of
airway smooth muscle. Eur Respir J 2000;15:1120e7.
13. Patel S, Joseph SK, Thomas AP. Molecular properties of inositol
1,4,5-trisphosphate receptors. Cell Calcium 1999;25:247e64.
14. Ma X, Cheng Z, Kong H, Ma X, Cheng Z, Kong H, et al. Changes
in biophysical and biochemical properties of single bronchial
smooth muscle cells from asthmatic subjects. Am J Physiol
Lung Cell Mol Physiol 2002;283:L1181e9.
1180 G. Pelaia et al.15. Somlyo AP, Somlyo AV. Signal transduction and regulation in
smooth muscle. Nature 1994;372:231e6.
16. Jude JA, Wylam ME, Walseth TF, Kannan MS. Calcium signaling
in airway smooth muscle. Proc Am Thorac Soc 2008;5:15e22.
17. Janssen LJ, Tazzeo T, Zuo J. Enhanced myosin phosphatase and
Ca2þ-uptake mediate adrenergic relaxation of airway smooth
muscle. Am J Respir Cell Mol Biol 2004;30:548e54.
18. Johnson EN, Druey KM. Heterotrimeric G protein signaling: role
in asthma and allergic inflammation. J Allergy Clin Immunol
2002;109:592e602.
19. Grieco MH, Pierson RN. Mechanism of bronchoconstriction due
to beta-adrenergic blockade. J Allergy Clin Immunol 1971;48:
143e52.
20. Vatrella A, Parrella R, Pelaia G, Biscione GL, Tranfa CME, De
Sarro GB, et al. Effects of non-bronchoconstrictive doses of in-
haled propranolol on airway responsiveness to methacholine.
Eur J Clin Pharmacol 2001;57:99e104.
21. Berridge MJ. Inositol trisphosphate and calcium oscillations. Bi-
ochem Soc Symp 2007;74:1e7.
22. Deshpande DA, White TA, Dogan S, Walseth TF, Panettieri RA,
Kannan MS. CD38/cyclic ADP-rybose signalling: role in the
regulation of calcium homeostasis in airway smooth muscle.
Am J Physiol Lung Cell Mol Physiol 2005;288:L773e88.
23. Ceyhan B, Celikel T. Effect of inhaled heparin on methacho-
line-induced bronchial hyperreactivity. Chest 1995;107:
1009e12.
24. Tranfa CME, Vatrella A, Parrella R, Pelaia G, Bariffi F,
Marsico SA. Effect of inhaled heparin on water-induced bron-
choconstriction in allergic asthmatics. Eur J Clin Pharmacol
2001;57:5e9.
25. McPherson PS, Campbell KP. The ryanodine receptor/Ca2þ
release channel. J Biol Chem 1993;268:13765e8.
26. Prakash YS, Kannan MS, Walseth TF, Sieck GC. Role of cyclic
ADP-ribose in the regulation of [Ca2þ]i in porcine tracheal
smooth muscle. Am J Physiol Cell Physiol 1998;274:C1653e60.
27. Berridge MJ, Bootman MD, Roderick HL. Calcium signaling:
dynamics, homeostasis and remodeling. Nat Rev Mol Cell Biol
2003;4:517e29.
28. Takasawa S, Ishida A, Nata K, Nagakawa K, Noguchi N, Tohgo A,
et al. Requirement of calmodulin-dependent protein kinase II
in cyclic ADP-ribose mediated intracellular Ca2þ mobilization.
J Biol Chem 1995;270:30257e9.
29. Lee HC. Potentiation of calcium- and caffeine-induced cal-
cium release by cyclic ADP-ribose. J Biol Chem 1993;268:
293e9.
30. Amrani Y, Tliba O, Deshpande DA, Walseth TF, Kannan MS,
Panettieri Jr RA. Bronchial hyperresponsiveness: insights into
new signaling molecules. Curr Opin Pharmacol 2004;4:230e4.
31. Deshpande DA, Walseth TF, Panettieri RA, Kannan MS. CD38-
cyclic ADP-rybose-mediated Ca2þ signaling contributes to
airway smooth muscle hyperresponsiveness. FASEB J 2003;
2003(17):452e4.
32. Tliba O, Deshpande D, Van Besien C, Chen H, Kannan M,
Panettieri RA, et al. IL-13 enhances agonist-evoked calcium
signals and contractile responses in airway smooth muscle. Br
J Pharmacol 2003;140:1159e62.
33. White TA, Kannan MS, Walseth TF. Intracellular calcium signal-
ing through the cADPR pathway is agonist specific in porcine
airway smooth muscle. FASEB J 2003;17:482e4.
34. Espinosa K, Bosse´ Y, Stankova J, Rola-Pleszczynski M. Cys-LT1
receptor upregulation by TGF-b and IL-13 is associated with
bronchial smooth muscle cell proliferation in response to
LTD4. J Allergy Clin Immunol 2003;111:1032e40.
35. Schmidlin F, Scherrer D, Daeffler L, Bertrand C, Landry Y,
Gies JP. Interleukin-1b induces bradykinin B2 receptor gene
expression through a prostanoid cyclic AMP-dependent
pathway in human bronchial smooth muscle cells. Mol
Pharmacol 1998;53:1009e15.36. Hotta K, Emala CW, Hirshman CA. TNF-a upregulates Gia and
Gqa protein expression and function in human airway smooth
muscle cells. Am J Physiol Lung Cell Mol Physiol 1999;276:
L405e11.
37. Shore SA, Moore PE. Regulation of b-adrenergic responses in
airway smooth muscle. Respir Physiol Neurobiol 2003;137:
179e95.
38. Murray RK, Fleischmann BK, Kotlikoff MI. Receptor-activated
Ca influx in human airway smooth muscle: use of Ca imaging
and perforated patch-clamp techniques. Am J Physiol Cell
Physiol 1993;264:C485e90.
39. Somlyo AP, Somlyo AV. Ca2þ sensitivity of smooth muscle and
nonmuscle myosin II: modulated by G proteins, kinases, and
myosin phosphatase. Physiol Rev 2003;83:1325e58.
40. Chiba Y, Misawa M. The role of RhoA-mediated Ca2þ sensitiza-
tion of bronchial smooth muscle contraction in airway
hyperresponsiveness. J Smooth Muscle Res 2004;40:155e67.
41. Sylvester JT. The tone of pulmonary smooth muscle: ROK and
Rho music? Am J Physiol Lung Cell Mol Physiol 2004;287:
L624e30.
42. Ito S, Kume H, Honjo H, Katoh H, Kodama I, Yamaki K, et al.
Possible involvement of Rho kinase in Ca2þ sensitization and
mobilization by MCh in tracheal smooth muscle. Am J Physiol
Lung Cell Mol Physiol 2001;280:L1218e24.
43. Chiba Y, Ueno A, Shinozaki K, Takeyama H, Nakazawa S,
Sakai H, et al. Involvement of RhoA-mediated Ca2þ sensiti-
zation in antigen-induced bronchial smooth muscle hyper-
responsiveness in mice. Respir Res 2005;6:4.
44. Sakai H, Otogoto S, Chiba Y, Abe K, Misawa M. Involvement of
p42/44 MAPK and RhoA protein in augmentation of ACh-
induced bronchial smooth muscle contraction by TNF-a in
rats. J Appl Physiol 2004;97:2154e9.
45. Sakai H, Shirai T, Yamamoto M, Chiba Y, Misawa M. Involvement
of M3 muscarinic receptors in ACh-induced increase in
membrane-associated RhoA of rat bronchial smooth muscle.
Biol Pharm Bull 2005;28:625e8.
46. Chiba Y, Sakai H, Misawa M. Endothelin-1-induced translo-
cation of RhoA is mediated by endothelin ETA receptors in
rat bronchial smooth muscle. Eur J Pharmacol 2005;517:
182e5.
47. Eto M, Ohmori T, Suzuki M, Furuya K, Morita F. A novel protein
phosphatase-1 inhibitory protein potentiated by protein kinase
C. Isolation from porcine aorta media and characterization.
J Biochem 1995;118:1104e7.
48. Sakai H, Chiba Y, Hirano T, Misawa M. Possible involvement of
CPI-17 in augmented bronchial smooth muscle contraction in
antigen-induced airway hyper-responsive rats. Mol Pharmacol
2005;68:145e51.
49. Sakai H, Chiba Y, Misawa M. Augmentation of endothelin-
1-induced phosphorylation of CPI-17 and myosin light chain in
bronchial smooth muscle from airway hyperresponsive rats.
Biol Pharm Bull 2006;29:1897e9.
50. Endou K, Iizuka K, Yoshii A, Tsukagoshi H, Ishizuka T, Dobashi K,
et al. 8-Bromo-cAMP decreases the Ca2þ sensitivity of airway
smooth muscle contraction through a mechanism distinct
from inhibition of Rho kinase. Am J Physiol Lung Cell Mol Phys-
iol 2004;287:L641e8.
51. Fixman ED, Stewart A, Martin JG. Basic mechanisms of
development of airway structural changes in asthma. Eur
Respir J 2007;29:379e89.
52. Tang MLK, Wilson JW, Stewart AG, Royce SG. Airway remodel-
ling in asthma: current understanding and implications for
future therapies. Pharmacol Ther 2006;112:474e88.
53. Pascual RM, Peters SP. Airway remodeling contributes to the
progressive loss of lung function in asthma: an overview.
J Allergy Clin Immunol 2005;116:477e86.
54. Cockcroft DW, Davis BE. Mechanisms of airway hyperrespon-
siveness. J Allergy Clin Immunol 2006;118:551e9.
ASM contraction and proliferation 118155. Sapienza S, Du T, Eidelman DH, Wang NS, Martin JG. Structural
changes in the airways of sensitised brown Norway rats after
antigen challenge. Am Rev Respir Dis 1991;144:423e7.
56. Pepe C, Foley S, Shannon J, Lemiere C, Olivenstein R, Ernst P,
et al. Differences in airway remodeling between subjects with
severe and moderate asthma. J Allergy Clin Immunol 2005;
116:544e9.
57. Cox G, Miller JD, McWilliams A, Fitzgerald JM, Lam S. Bronchial
thermoplasty for asthma. Am J Respir Crit Care Med 2006;173:
965e9.
58. Johnson PR, Roth M, Tamm M, Hughes M, Ge Q, King G, et al.
Airway smooth muscle cell proliferation is increased in asthma.
Am J Respir Crit Care Med 2001;164:474e7.
59. Hirst SJ, Martin JG, Bonacci JV, Chan V, Fixman ED, Hamid QA,
et al. Proliferative aspects of airway smooth muscle. J Allergy
Clin Immunol 2004;114:S2e17.
60. Chambers LS, Black JL, Ge Q, Carlin SM, Au WW, Poniris M,
et al. PAR-2 activation, PGE2, and COX-2 in human asthmatic
and nonasthmatic airway smooth muscle cells. Am J Physiol
Lung Cell Mol Physiol 2003;285:L619e27.
61. Belvisi MG, Saunders M, Yacoub M, Mitchell JA. Expression of
cyclo-oxygenase-2 in human airway smooth muscle is associ-
ated with profound reductions in cell growth. Br J Pharmacol
1998;125:1102e8.
62. Zhou L, Hershenson MB. Mitogenic signaling pathways in
airway smooth muscle. Respir Physiol Neurobiol 2003;137:
295e308.
63. Ammit AJ, Kane SA, Panettieri RA. Activation of K-p21ras and
N-p21ras, but not H-p21ras, is necessary for mitogen-induced
human airway smooth muscle proliferation. Am J Respir Cell
Mol Biol 1999;21:719e27.
64. Ramakrishnan M, Musa NL, Li J, Liu PT, Pestell RG,
Hershenson MB. Catalytic activation of extracellular sig-
nal-regulated kinases induces cyclin D1 expression in pri-
mary tracheal myocytes. Am J Respir Cell Mol Biol 1998;
18:736e40.
65. Fernandes D, Guida E, Koutsoubos V, Harris T, Vadiveloo P,
Wilson JW, et al. Glucocorticoids inhibit proliferation, cyclin
D1 expression, and retinoblastoma protein phosphorylation,
but not activity of the extracellular-regulated kinases in
human cultured airway smooth muscle. Am J Respir Cell Mol
Biol 1999;21:77e88.
66. Orsini MJ, Krymskaya VP, Eszterhas AJ, Benovic JL,
Panettieri Jr RA, Penn RB. MAPK superfamily activation in
human airway smooth muscle: mitogenesis requires prolonged
p42/p44 activation. Am J Physiol Lung Cell Mol Physiol 1999;
277:L479e88.
67. Lee JH, Johnson PR, Roth M, Hunt NH, Black JL. ERK activation
and mitogenesis in human airway smooth muscle cells. Am J
Physiol Lung Cell Mol Physiol 2001;280:L1019e29.
68. Fernandes DJ, Ravenhall CE, Harris T, Tran T, Vlahos R. Contri-
bution of the p38MAPK signalling pathway to proliferation inhuman cultured airway smooth muscle cells is mitogen-
specific. Br J Pharmacol 2004;142:1182e90.
69. Nath P, Leung SY, Williams A, Noble A, Chakravarty SDS,
Luedtke GR, et al. Importance of p38mitogen-activated protein
kinase pathway in allergic airway remodelling and bronchial hy-
perresponsiveness. Eur J Pharmacol 2006;544:160e7.
70. Eynott PR, Nath P, Leung SY, Adcock IM, Bennett BL, Chung KF.
Allergen-induced inflammation and airway epithelial and
smooth muscle cell proliferation: role of Jun N-terminal
kinase. Br J Pharmacol 2003;140:1373e80.
71. Nath P, Eynott P, Leung SY, Adcock IM, Bennett BL, Chung KF.
Potential role of c-Jun NH2-terminal kinase in allergic airway
inflammation and remodelling: effects of SP600125. Eur J
Pharmacol 2005;506:273e83.
72. Cantley LC. The phosphoinositide 3-kinase pathway. Science
2002;296:1655e7.
73. Wymann MP, Zvelebil M, Laffargue M. Phosphoinositide
3-kinase signalling: which way to target? Trends Pharmacol
Sci 2003;24:366e76.
74. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S,
Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S
transition is mediated by effects on cyclin D1 mRNA and
protein stability. J Biol Chem 1998;273:14424e9.
75. Scott PH, Belham CM, al-Hafidh J, Chilvers ER, Peacock AJ,
Gould GW, et al. A regulatory role for cAMP in phosphatidylino-
sitol 3-kinase/p70 ribosomal S6 kinase-mediated DNA synthesis
in platelet-derived-growth-factor-stimulated bovine airway
smooth muscle cells. Biochem J 1996;318:965e71.
76. Krymskaya VP, Penn RB, Orsini MJ, Scott PH, Plevin RJ,
Walker TR, et al. Phosphatidylinositol 3-kinase mediates mito-
gen-induced human airway smooth muscle cell proliferation.
Am J Physiol Lung Cell Mol Physiol 1999;277:L65e78.
77. Page K, Li J, Hodge J, Liu P, Vanden Hoek T, Becker L, et al.
Characterization of a Rac1 signaling pathway to cyclin D1 ex-
pression in airway smooth muscle cells. J Biol Chem 1999;
274:22065e71.
78. Walker TR, Moore SM, Lanson MF, Panettieri Jr RA, Chilvers ER.
Platelet-derived growth factor-BB and thrombin activate phos-
phoinositide 3-kinase and protein kinase B: role in mediating
airway smooth muscle proliferation. Mol Pharmacol 1998;54:
1007e15.
79. Roth M, Johnson PRA, Rudiger JJ, King GG, Ge Q, Burgess JK,
et al. Interaction between glucocorticoids and b2-agonists on
bronchial airway smooth muscle cells through synchronised
cellular signaling. Lancet 2002;360:1293e9.
80. Roth M, Johnson PRA, Borger P, Bihl MP, Rudiger JJ, King GG,
et al. Dysfunctional interaction of C/EBPa and the glucocorti-
coid receptor in asthmatic bronchial smooth-muscle cells. N
Engl J Med 2004;351:560e74.
81. Borger P, Tamm M, Black JL, Roth M. Asthma: is it due to an
abnormal airway smooth muscle cell? Am J Respir Crit Care
Med 2006;174:367e72.
